APPA: a well-tolerated, oral, multi-pathway candidate for osteoarthritis

APPA is a patented, fixed-dose oral combination of two synthetic small molecules, apocynin and paeonol. It has completed Phase 2b development in knee OA.

OA is not simply wear and tear. Inflammation, oxidative stress and aging cells in the joint all drive pain and damage, so an effective treatment needs to act on more than one pathway. APPA modulates the Nrf2 and NF-κB pathways, which control the joint’s inflammatory and antioxidant responses. In laboratory studies it reduced inflammatory activity and oxidative stress in human cartilage cells, reduced markers of cell aging, and dampened inflammatory activity in neutrophils without impairing their defensive function.

In the clinic, APPA has been generally well tolerated in three trials, with no maximum tolerated dose reached at up to 1,600 mg twice daily. Phase 2b showed a dose-related efficacy signal, strongest in patients with higher baseline pain. See Human Data.

Intellectual property and regulatory status

  • Granted patents covering APPA in 37 major markets.
  • A patented liquid formulation of APPA, granted in the EU, US and other markets.
  • A further patent application covering effects on cell aging in a range of age-related conditions.
  • Innovation Passport from the UK MHRA.

AKL is seeking a partner for APPA. Please contact us.

APPA acts on several pathways that drive OA. Laboratory and preclinical findings; see the references on the Human and Animal Data pages.